UBS keeps EUR 260 target for Sartorius Stedim stock

Published on 10/20/2026 at 10:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half 2026 revenue reached EUR 1.527 billion. Sartorius Stedim stock costs EUR 213.50 on October 20, 2026, 0.88 percent below EUR 215.40.

Analyst view and reporting dates

On October 15, 2026, UBS kept a EUR 260 target and Buy rating for Sartorius Stedim.
First-half 2026 revenue reached EUR 1.527 billion and underlying EBITDA margin was 31.40 percent.
Sartorius Stedim stock trades at EUR 213.50 at 10:33 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.88 percent below the Xetra close of October 19, 2026.
The next earnings release is scheduled for October 21, 2026, followed by the conference call on October 22, 2026.

Extreme Nahaufnahme einer transparenten Filtermembran mit Flüssigkeitstropfen — Sartorius Stedim Biotech Makroaufnahme einer transparenten Filtermembran mit feinen Flüssigkeitstropfen, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech (ISIN FR0013154002) was trading at EUR 213.50 at Lang & Schwarz on October 20, 2026, at 10:33 a.m. CEST, down 0.88 percent versus the Xetra close of October 19, 2026 at EUR 215.40. The latest analyst signal came from UBS, which kept a Buy rating and a EUR 260 target on October 15, 2026, according to MarketScreener.

First-half figures set the base

The company entered the autumn reporting period with a measurable recovery in its operating profile. First-half 2026 revenue was EUR 1.527 billion, while underlying earnings before interest, taxes, depreciation and amortization reached EUR 463.70 million and the underlying margin was 31.40 percent, according to Ideal Investor. The same report cited fiscal-year revenue guidance of EUR 3.1538 billion.

Three events frame the recovery

On July 22, 2026, Sartorius Stedim reported first-half revenue of EUR 1.527 billion and kept its fiscal-year growth outlook at 6 to 10 percent in constant currencies, according to Sartorius Stedim. On October 6, 2026, RBC retained an Outperform rating and a EUR 210 target, as reported by Finanzen AT. On October 15, 2026, UBS kept its Buy rating and EUR 260 target, according to MarketScreener.

What does EUR 260 mean for valuation?

The UBS target stands 21.78 percent above the Lang & Schwarz price of EUR 213.50. That spread gives the analyst call more weight than the modest daily decline, while the upcoming results remain the next test of whether the recovery in bioprocess demand is translating into profitable growth.

Reporting dates are close

MarketScreener lists October 21, 2026 as the earnings release date for the third quarter. The company investor-relations page schedules a conference call for October 22, 2026 at 1:00 p.m. CEST, according to Sartorius Stedim. Those dates put operating trends, margin delivery and the 2026 outlook directly in front of investors.

Stock trades below the Xetra close

The current euro quote sits below the previous Xetra session, but the longer valuation discussion still centers on the EUR 260 UBS target and the company's 2026 revenue trajectory. Sartorius Stedim is listed on Euronext Paris and focuses on equipment, consumables and services for biopharmaceutical production.

The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.